Rivaroxaban can reduce VTE in cancer patients

Print Friendly, PDF & Email


Rivaroxaban
In the phase 3 CASSINI trial, prophylaxis with rivaroxaban reduced the rate of venous thromboembolism (VTE) and VTE-related death in high-risk ambulatory cancer patients receiving systemic therapy. The reduction in VTE and related death was not statistically significant in the primary analysis, which included a period of time after treatment had stopped. However,... [Read Article]
Print Friendly, PDF & Email

Data support apixaban for cancer-associated VTE, doc says

Print Friendly, PDF & Email


2018 ASH Annual Meeting
©ASH/Scott Morgan 2018
Apixaban is as safe as, and more effective than, dalteparin for patients with cancer-associated venous thromboembolism (VTE), according to the ADAM VTE trial. Patients who received apixaban in this trial had similar rates of major bleeding and clinically relevant non-major bleeding as patients who received dalteparin. However,... [Read Article]
Print Friendly, PDF & Email

New VTE guidelines include over 150 recommendations

Print Friendly, PDF & Email


Thrombus
Image by Kevin MacKenzie
The American Society of Hematology (ASH) has released a new set of guidelines for the prevention, diagnosis, and management of venous thromboembolism (VTE). The new guidelines contain more than 150 individual recommendations, including sections devoted to managing VTE during pregnancy and in pediatric patients. Guideline highlights cited by some of... [Read Article]
Print Friendly, PDF & Email

EC approves product for hemophilia A

Print Friendly, PDF & Email


Damoctocog alfa pegol (Jivi)
Photo from Bayer
The European Commission (EC) has approved damoctocog alfa pegol (Jivi®), a recombinant human factor VIII therapy. Damoctocog alfa pegol (formerly BAY94-9027) is approved for the treatment and prophylaxis of bleeding in previously treated patients age 12 and older who have hemophilia A. The approval is valid in... [Read Article]
Print Friendly, PDF & Email

Education can improve adherence to VTE prophylaxis

Print Friendly, PDF & Email


Elliott Haut (left) and team
Photo courtesy of
Johns Hopkins Medicine
Education can improve adherence to venous thromboembolism (VTE) prophylaxis among hospitalized patients, according to researchers. They assessed data from more than 19,000 hospital stays and found that “real-time” educational interventions directed toward patients and nurses significantly reduced nonadministration of prescribed VTE prophylaxis. However,... [Read Article]
Print Friendly, PDF & Email

Score can predict thrombosis in ITP

Print Friendly, PDF & Email


Thrombus
Image by Andre E.X. Brown
New research suggests a scoring system can predict the risk of thrombosis in patients with immune thrombocytopenia (ITP) who are taking anticoagulants. Researchers tested their Thrombosis and Thrombocytopenia (TH2) risk assessment score in a small group of ITP patients on anticoagulants, and the score identified all seven patients... [Read Article]
Print Friendly, PDF & Email

Vaccine inhibits thrombus formation in mice

Print Friendly, PDF & Email


Lab mouse
Investigators designed an antiplatelet vaccine they say could be a novel therapy to prevent recurrent ischemic stroke. The vaccine inhibits S100A9/CD36 signaling in platelets, which is a key signal in arterial thrombosis but not hemostasis. Mice immunized with the vaccine experienced an antithrombotic effect that lasted 84 days. The vaccine inhibited thrombus formation... [Read Article]
Print Friendly, PDF & Email

Aspirin prevents VTE as well as anticoagulants, study suggests

Print Friendly, PDF & Email


Aspirin tablets
Photo by Sage Ross
Putting patients on aspirin following a knee replacement is a safe, cost-effective alternative to treatment with anticoagulants, according to researchers. A study of more than 40,000 patients revealed a similar incidence of venous thromboembolism (VTE) or death after total knee arthroplasty (TKA) in patients receiving aspirin and patients... [Read Article]
Print Friendly, PDF & Email

Canada approves Jivi for hemophilia A

Print Friendly, PDF & Email


U.S. version of Jivi®
Photo from Bayer
Health Canada has approved Jivi® (antihemophilic factor [recombinant, B-domain deleted, PEGylated]) for use in patients with hemophilia A. Jivi (formerly BAY94-9027) is a DNA-derived, factor VIII concentrate developed by Bayer. Health Canada has approved Jivi for use as routine prophylaxis to prevent or reduce the frequency of... [Read Article]
Print Friendly, PDF & Email

SNPs linked to bleeding in African Americans on warfarin

Print Friendly, PDF & Email


Warfarin tablets
Researchers say they have identified single-nucleotide polymorphisms (SNPs) that are associated with increased bleeding risk in African-American patients on warfarin. A retrospective study revealed four SNPs associated with increased bleeding risk in African Americans with an international normalized ratio (INR) of less than 4. One of these SNPs was seen in more... [Read Article]
Print Friendly, PDF & Email

Inhibitor receives orphan designation for ITP

Print Friendly, PDF & Email


Platelets (blue) surrounded by red blood cells
Image from Graham Beards
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PRN1008 for the treatment of patients with immune thrombocytopenia (ITP). PRN1008 is an oral, reversible, covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed by Principia Biopharma, Inc. Principia is conducting a... [Read Article]
Print Friendly, PDF & Email